Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNX NASDAQ:MTEM NYSE:MYOV NASDAQ:RYTM NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.62 million shsN/AMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsRYTMRhythm Pharmaceuticals$96.22-1.7%$93.40$45.90▼$106.52$6.39B2.23543,802 shs532,025 shsSTOKStoke Therapeutics$23.46-1.8%$16.05$5.35▼$24.60$1.29B1.14910,639 shs1.03 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%0.00%MTEMMolecular Templates0.00%0.00%0.00%0.00%-99.99%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%RYTMRhythm Pharmaceuticals0.00%-5.78%-1.42%+54.22%+93.91%STOKStoke Therapeutics0.00%+13.44%+28.83%+100.51%+62.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.62 million shsN/AMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsRYTMRhythm Pharmaceuticals$96.22-1.7%$93.40$45.90▼$106.52$6.39B2.23543,802 shs532,025 shsSTOKStoke Therapeutics$23.46-1.8%$16.05$5.35▼$24.60$1.29B1.14910,639 shs1.03 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%0.00%MTEMMolecular Templates0.00%0.00%0.00%0.00%-99.99%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%RYTMRhythm Pharmaceuticals0.00%-5.78%-1.42%+54.22%+93.91%STOKStoke Therapeutics0.00%+13.44%+28.83%+100.51%+62.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNXAthenex 0.00N/AN/AN/AMTEMMolecular Templates 0.00N/AN/AN/AMYOVMyovant Sciences 0.00N/AN/AN/ARYTMRhythm Pharmaceuticals 3.07Buy$101.575.56% UpsideSTOKStoke Therapeutics 3.22Buy$25.579.00% UpsideCurrent Analyst Ratings BreakdownLatest STOK, RYTM, MYOV, ATNX, and MTEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$28.008/13/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/13/2025STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $22.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $100.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$119.00 ➝ $120.008/6/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$130.00 ➝ $135.008/5/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$100.00 ➝ $109.007/18/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $105.007/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.007/10/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/10/2025RYTMRhythm PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$76.00 ➝ $110.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35RYTMRhythm Pharmaceuticals$130.13M49.11N/AN/A$0.35 per share274.91STOKStoke Therapeutics$36.56M35.16N/AN/A$4.32 per share5.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/AMTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/AMYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ARYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8527.60N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)Latest STOK, RYTM, MYOV, ATNX, and MTEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNXAthenexN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNXAthenex3.081.090.72MTEMMolecular TemplatesN/A1.561.56MYOVMyovant SciencesN/A1.571.45RYTMRhythm PharmaceuticalsN/A2.792.64STOKStoke TherapeuticsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNXAthenex30.48%MTEMMolecular Templates95.47%MYOVMyovant Sciences30.62%RYTMRhythm PharmaceuticalsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipATNXAthenex9.20%MTEMMolecular Templates13.90%MYOVMyovant Sciences1.90%RYTMRhythm Pharmaceuticals6.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNXAthenex6528.66 million7.87 millionOptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableSTOK, RYTM, MYOV, ATNX, and MTEM HeadlinesRecent News About These CompaniesStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Brokerages4 hours ago | marketbeat.comSiren L.L.C. Buys 247,347 Shares of Stoke Therapeutics, Inc. $STOKSeptember 13 at 5:56 AM | marketbeat.comJacobs Levy Equity Management Inc. Purchases New Stake in Stoke Therapeutics, Inc. $STOKSeptember 13 at 3:41 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 5.4% - Time to Sell?September 11, 2025 | marketbeat.comWhich Is a Better Investment, ACADIA Pharmaceuticals Inc. or Travere Therapeutics, Inc. Stock?September 11, 2025 | aaii.comAStoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome DrugSeptember 11, 2025 | finance.yahoo.comStoke Therapeutics (NASDAQ:STOK) Hits New 1-Year High - Still a Buy?September 10, 2025 | marketbeat.comStoke Therapeutics, Inc. $STOK Shares Sold by Trexquant Investment LPSeptember 10, 2025 | marketbeat.comInvesco Ltd. Raises Stock Holdings in Stoke Therapeutics, Inc. $STOKSeptember 10, 2025 | marketbeat.comStoke Therapeutics, Inc. $STOK Shares Bought by Granahan Investment Management LLCSeptember 7, 2025 | marketbeat.comStoke Therapeutics, Inc. $STOK is Checkpoint Capital L.P.'s 7th Largest PositionSeptember 6, 2025 | marketbeat.com16,119 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Russell Investments Group Ltd.September 6, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 850 Shares of StockSeptember 5, 2025 | marketbeat.comEdward Md Kaye Sells 1,029 Shares of Stoke Therapeutics (NASDAQ:STOK) StockSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 5,501 SharesSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 6,345 SharesSeptember 5, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells $299,280.40 in StockSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $300,529.08 in StockSeptember 5, 2025 | marketbeat.comEdward Md Kaye Sells 45,996 Shares of Stoke Therapeutics (NASDAQ:STOK) StockSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Buys Shares of 30,085 Stoke Therapeutics, Inc. $STOKSeptember 5, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Hits New 1-Year High - Here's WhySeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTOK, RYTM, MYOV, ATNX, and MTEM Company DescriptionsAthenex NASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Myovant Sciences NYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Rhythm Pharmaceuticals NASDAQ:RYTM$96.22 -1.70 (-1.74%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$96.28 +0.06 (+0.06%) As of 09/12/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Stoke Therapeutics NASDAQ:STOK$23.46 -0.42 (-1.76%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.70 +0.24 (+1.02%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
